8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 27, 2026·SEC
Material company update
Feb 24, 2026·SEC
TransMedics Group, Inc.(TMDX)Earnings, Financials & Key Ratios
TMDX•NASDAQ
$72.92
$2.52B mkt cap·15.0× P/E·Price updated May 6, 2026
AboutTransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Show more
- Revenue$605M+37.1%
- EBITDA$136M+137.1%
- Net Income$190M+436.6%
- EPS (Diluted)4.87+382.2%
- Gross Margin59.92%+0.9%
- EBITDA Margin22.42%+72.9%
- Operating Margin17.93%+111.2%
- Net Margin31.43%+291.3%
- ROE54.24%+179.7%
- ROIC18.84%+123.9%
- Debt/Equity0.99-56.2%
- Interest Coverage8.80+152.7%
TMDX Key Insights
TransMedics Group, Inc. (TMDX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 22.1% free cash flow margin
- ✓Strong 5Y sales CAGR of 88.2%
- ✓Good 3Y average ROE of 19.4%
✗Weaknesses
- ✗Weak momentum: RS Rating 16 (bottom 16%)
- ✗Shares diluted 15.1% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TMDX Price & Volume
TransMedics Group, Inc. (TMDX) stock price & volume — 10-year historical chart
Loading chart...
TMDX Growth Metrics
TransMedics Group, Inc. (TMDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years88.21%
3 Years86.42%
TTM30.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM251.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM221.32%
Return on Capital
10 Years-28.43%
5 Years-7.38%
3 Years3.88%
Last Year12.6%
TMDX Recent Earnings
TransMedics Group, Inc. (TMDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 5, 2026EPS
$0.30
Est $0.62
-51.6%
Revenue
$174M
Est $174M
-0.3%
Q1 2026
Feb 24, 2026EPS
$0.57
Est $0.41
+39.0%
Revenue
$161M
Est $155M
+3.5%
Q4 2025
Oct 29, 2025EPS
$0.66
Est $0.37
+78.4%
Revenue
$144M
Est $155M
-7.5%
Q3 2025
Jul 30, 2025EPS
$0.92
Est $0.48
+91.7%
Revenue
$157M
Est $142M
+11.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.30vs $0.62-51.6% | $174Mvs $174M-0.3% |
| Q1 2026 | Feb 24, 2026 | $0.57vs $0.41+39.0% | $161Mvs $155M+3.5% |
| Q4 2025 | Oct 29, 2025 | $0.66vs $0.37+78.4% | $144Mvs $155M-7.5% |
| Q3 2025 | Jul 30, 2025 | $0.92vs $0.48+91.7% | $157Mvs $142M+11.1% |
Based on last 12 quarters of dataView full earnings history →
TMDX Peer Comparison
TransMedics Group, Inc. (TMDX) competitors in Device suppliers, distribution, and services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AVXL | 309.52M | 3.34 | -6.19 | -31.55% | ||||
 STVN | 5.19B | 19.00 | 33.04 | 3.21% | 11.79% | 9.72% | 0.32 | |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 LIVN | 3.62B | 66.26 | -14.89 | 10.74% | 7.47% | 9.13% | 0.39 | |
 ATRC | 1.42B | 28.01 | -116.71 | 14.88% | -0.83% | -0.95% | 0.18 | |
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 | |
 MMSI | 3.68B | 61.63 | 28.93 | 11.66% | 9.03% | 8.95% | 0.57 | |
 ITGR | 2.97B | 86.29 | 29.86 | 7.57% | 7.67% | 8.23% | 0.80 |
Compare TMDX vs Peers
TransMedics Group, Inc. (TMDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TMDX Income Statement
TransMedics Group, Inc. (TMDX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 7.68M | 13.02M | 23.6M | 25.64M | 30.26M | 93.46M | 241.62M | 441.54M | 605.49M | 635.89M |
| Revenue Growth % | 23.77% | 69.38% | 81.33% | 8.62% | 18.03% | 208.83% | 158.53% | 82.74% | 37.13% | 30.24% |
| Cost of Goods Sold | 5.55M | 7.28M | 9.74M | 9M | 9.1M | 28.19M | 87.53M | 179.46M | 242.69M | 260.15M |
| COGS % of Revenue | 72.19% | 55.95% | 41.27% | 35.12% | 30.08% | 30.16% | 36.23% | 40.64% | 40.08% | - |
| Gross Profit | 2.14M▲ 0% | 5.73M▲ 168.3% | 13.86M▲ 141.8% | 16.64M▲ 20.0% | 21.16M▲ 27.2% | 65.27M▲ 208.5% | 154.09M▲ 136.1% | 262.08M▲ 70.1% | 362.81M▲ 38.4% | 375.74M▲ 0% |
| Gross Margin % | 27.81% | 44.05% | 58.73% | 64.88% | 69.92% | 69.84% | 63.77% | 59.36% | 59.92% | 59.09% |
| Gross Profit Growth % | 178.98% | 168.32% | 141.77% | 20% | 27.2% | 208.48% | 136.08% | 70.08% | 38.43% | - |
| Operating Expenses | 22.56M | 25.97M | 43.47M | 43.02M | 60.59M | 96.71M | 182.82M | 224.59M | 254.22M | 281.3M |
| OpEx % of Revenue | 293.6% | 199.52% | 184.15% | 167.79% | 200.21% | 103.48% | 75.66% | 50.86% | 41.99% | - |
| Selling, General & Admin | 7.61M | 12.31M | 23.6M | 24.19M | 38.28M | 69.9M | 119.55M | 168.62M | 185.17M | 204.53M |
| SG&A % of Revenue | 98.97% | 94.61% | 99.97% | 94.34% | 126.51% | 74.79% | 49.48% | 38.19% | 30.58% | - |
| Research & Development | 14.96M | 13.66M | 19.87M | 18.83M | 22.3M | 26.81M | 63.27M | 55.97M | 69.06M | 76.77M |
| R&D % of Revenue | 194.63% | 104.91% | 84.18% | 73.45% | 73.7% | 28.69% | 26.18% | 12.68% | 11.4% | - |
| Other Operating Expenses | 0 | -213K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -20.43M▲ 0% | -20.24M▲ 0.9% | -29.6M▼ 46.3% | -26.38M▲ 10.9% | -39.43M▼ 49.4% | -31.44M▲ 20.3% | -28.73M▲ 8.6% | 37.5M▲ 230.5% | 108.58M▲ 189.6% | 94.44M▲ 0% |
| Operating Margin % | -265.79% | -155.47% | -125.42% | -102.91% | -130.29% | -33.64% | -11.89% | 8.49% | 17.93% | 14.85% |
| Operating Income Growth % | 11.14% | 0.93% | -46.28% | 10.87% | -49.44% | 20.27% | 8.62% | 230.53% | 189.59% | - |
| EBITDA | -19.8M | -19.47M | -28.38M | -24.81M | -37.61M | -27.96M | -20.55M | 57.25M | 135.77M | 115.48M |
| EBITDA Margin % | -257.59% | -149.56% | -120.24% | -96.75% | -124.28% | -29.92% | -8.51% | 12.97% | 22.42% | 18.16% |
| EBITDA Growth % | 12.25% | 1.66% | -45.78% | 12.59% | -51.61% | 25.66% | 26.5% | 378.61% | 137.13% | 55.83% |
| D&A (Non-Cash Add-back) | 630K | 769K | 1.22M | 1.58M | 1.82M | 3.48M | 8.18M | 19.76M | 27.18M | 21.05M |
| EBIT | -19.72M | -21M | -29.15M | -24.73M | -40.3M | -32.44M | -15.88M | 50.19M | 121.3M | 91.17M |
| Net Interest Income | -524K | -2.42M | -3.56M | -2.33M | -3.87M | -2.83M | 1.71M | -14.41M | -13.78M | -7.82M |
| Interest Income | 548K | 0 | 790K | 1.65M | 0 | 900K | 12.5M | 0 | 0 | 2.5M |
| Interest Expense | 1.07M | 2.42M | 4.35M | 3.98M | 3.87M | 3.73M | 10.79M | 14.41M | 13.78M | 3.15M |
| Other Income/Expense | -365K | -3.48M | -3.9M | -2.33M | -4.75M | -4.73M | 2.06M | -1.72M | -1.06M | -5.11M |
| Pretax Income | -20.79M▲ 0% | -23.71M▼ 14.1% | -33.51M▼ 41.3% | -28.72M▲ 14.3% | -44.18M▼ 53.8% | -36.16M▲ 18.1% | -26.67M▲ 26.3% | 35.78M▲ 234.2% | 107.52M▲ 200.5% | 89.33M▲ 0% |
| Pretax Margin % | -270.54% | -182.18% | -141.95% | -112% | -145.99% | -38.7% | -11.04% | 8.1% | 17.76% | 14.05% |
| Income Tax | 32K | 41K | 40K | 32K | 36K | 66K | -1.64M | 316K | -82.77M | -84.93M |
| Effective Tax Rate % | -0.15% | -0.17% | -0.12% | -0.11% | -0.08% | -0.18% | 6.16% | 0.88% | -76.98% | -95.08% |
| Net Income | -20.82M▲ 0% | -23.76M▼ 14.1% | -33.55M▼ 41.2% | -28.75M▲ 14.3% | -44.22M▼ 53.8% | -36.23M▲ 18.1% | -25.03M▲ 30.9% | 35.46M▲ 241.7% | 190.29M▲ 436.6% | 171.92M▲ 0% |
| Net Margin % | -270.96% | -182.5% | -142.12% | -112.13% | -146.11% | -38.77% | -10.36% | 8.03% | 31.43% | 27.04% |
| Net Income Growth % | 13.47% | -14.09% | -41.21% | 14.31% | -53.8% | 18.06% | 30.92% | 241.7% | 436.58% | 251.23% |
| Net Income (Continuing) | -20.82M | -23.76M | -33.55M | -28.75M | -44.22M | -36.23M | -25.03M | 35.46M | 190.29M | 171.92M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.44▲ 0% | -1.23▲ 14.6% | -2.36▼ 91.9% | -1.16▲ 50.8% | -1.60▼ 37.9% | -1.23▲ 23.1% | -0.77▲ 37.4% | 1.01▲ 231.2% | 4.87▲ 382.2% | 4.75▲ 0% |
| EPS Growth % | 13.25% | 14.58% | -91.87% | 50.85% | -37.93% | 23.13% | 37.4% | 231.17% | 382.18% | 221.32% |
| EPS (Basic) | -1.44 | -1.23 | -2.36 | -1.16 | -1.60 | -1.23 | -0.77 | 1.07 | 5.60 | - |
| Diluted Shares Outstanding | 14.48M | 19.25M | 14.2M | 24.7M | 27.62M | 29.56M | 32.52M | 35.22M | 40.54M | 36.19M |
| Basic Shares Outstanding | 14.48M | 19.25M | 14.2M | 24.7M | 27.62M | 29.56M | 32.52M | 33.23M | 33.99M | 34.38M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TMDX Balance Sheet
TransMedics Group, Inc. (TMDX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 34.04M | 34.79M | 100M | 146.77M | 118.7M | 252.29M | 510.65M | 497.22M | 637.78M | 619.28M |
| Cash & Short-Term Investments | 24.66M | 20.24M | 80.69M | 125.64M | 92.45M | 201.18M | 394.81M | 336.65M | 488.37M | 461.74M |
| Cash Only | 11.94M | 20.24M | 20.09M | 24.58M | 25.58M | 201.18M | 394.81M | 336.65M | 488.37M | 461.74M |
| Short-Term Investments | 12.73M | 0 | 60.6M | 101.06M | 66.87M | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 925K | 3.44M | 6.56M | 6.86M | 5.93M | 27.61M | 63.58M | 97.72M | 84.28M | 90.73M |
| Days Sales Outstanding | 43.93 | 96.4 | 101.42 | 97.72 | 71.57 | 107.83 | 96.04 | 80.78 | 50.81 | 51.74 |
| Inventory | 7.97M | 9.28M | 11.22M | 11.93M | 14.86M | 20.61M | 44.23M | 46.55M | 48.88M | 49.89M |
| Days Inventory Outstanding | 524.41 | 464.93 | 420.27 | 483.77 | 595.8 | 266.82 | 184.46 | 94.69 | 73.52 | 63.89 |
| Other Current Assets | 0 | 0 | 1.54M | 2.33M | 5.46M | 2.9M | 8.03M | 16.29M | 16.25M | 16.92M |
| Total Non-Current Assets | 2.96M | 7.36M | 5.3M | 5.26M | 16.19M | 24.85M | 195.39M | 306.86M | 430.59M | 815.54M |
| Property, Plant & Equipment | 2.46M | 3.47M | 4.79M | 4.75M | 15.69M | 24.35M | 180.49M | 292.45M | 332.81M | 700.97M |
| Fixed Asset Turnover | 3.13x | 3.75x | 4.93x | 5.39x | 1.93x | 3.84x | 1.34x | 1.51x | 1.82x | 1.52x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 11.99M | 11.55M | 11.55M | 11.55M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 2.35M | 2.15M | 1.95M | 0 |
| Long-Term Investments | 500K | 500K | 500K | 0 | 500K | 500K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 6K | 3.39M | 6K | 506K | 0 | 0 | 562K | 708K | 739K | 22.73M |
| Total Assets | 37M▲ 0% | 42.16M▲ 13.9% | 105.3M▲ 149.8% | 152.03M▲ 44.4% | 134.89M▼ 11.3% | 277.15M▲ 105.5% | 706.05M▲ 154.8% | 804.08M▲ 13.9% | 1.07B▲ 32.9% | 1.43B▲ 0% |
| Asset Turnover | 0.21x | 0.31x | 0.22x | 0.17x | 0.22x | 0.34x | 0.34x | 0.55x | 0.57x | 0.59x |
| Asset Growth % | -36.32% | 13.93% | 149.78% | 44.38% | -11.27% | 105.46% | 154.76% | 13.88% | 32.87% | 142.01% |
| Total Current Liabilities | 10.9M | 12.55M | 16.11M | 11.88M | 23.24M | 23.66M | 54.93M | 59.91M | 89.31M | 91.92M |
| Accounts Payable | 3.52M | 4.72M | 7.25M | 1.21M | 6.65M | 3.34M | 12.72M | 10.29M | 10.35M | 11.15M |
| Days Payables Outstanding | 231.25 | 236.55 | 271.55 | 48.89 | 266.68 | 43.26 | 53.03 | 20.93 | 15.57 | 15.15 |
| Short-Term Debt | 1.8M | 0 | 0 | 0 | 0 | 0 | 0 | 2.73M | 13.31M | 18.51M |
| Deferred Revenue (Current) | 239K | 306K | 166K | 263K | 250K | 241K | 1.96M | 1.74M | 2.9M | 10.72M |
| Other Current Liabilities | 569K | 655K | 370K | 6.38M | 11.16M | 8.82M | 17.92M | 45.15M | 62.74M | 59.32M |
| Current Ratio | 3.12x | 2.77x | 6.21x | 12.36x | 5.11x | 10.66x | 9.30x | 8.30x | 7.14x | 7.14x |
| Quick Ratio | 2.39x | 2.03x | 5.51x | 11.35x | 4.47x | 9.79x | 8.49x | 7.52x | 6.59x | 6.59x |
| Cash Conversion Cycle | 337.09 | 324.78 | 250.15 | 532.6 | 400.69 | 331.39 | 227.47 | 154.53 | 108.76 | 100.48 |
| Total Non-Current Liabilities | 194.83M | 34.43M | 34.53M | 36.26M | 43.8M | 66.11M | 513.91M | 515.56M | 505.97M | 848.89M |
| Long-Term Debt | 6.85M | 33.67M | 34.15M | 34.66M | 35.2M | 58.7M | 506.2M | 509.31M | 456.38M | 800.24M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 8.6M | 7.42M | 7.71M | 6.25M | 0 | 9.34M |
| Deferred Tax Liabilities | -1.11M | -759K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 187.98M | 759K | 389K | 1.6M | 0 | 0 | 0 | 0 | 49.59M | 98.24M |
| Total Liabilities | 205.72M | 46.98M | 50.65M | 48.13M | 67.04M | 89.77M | 568.85M | 575.47M | 595.27M | 940.81M |
| Total Debt | 8.65M | 33.67M | 34.15M | 34.66M | 43.8M | 67.56M | 515.95M | 518.29M | 469.69M | 818.75M |
| Net Debt | -3.28M | 13.43M | 14.05M | 10.08M | 18.22M | -133.63M | 121.13M | 181.64M | -18.68M | 357.01M |
| Debt / Equity | - | - | 0.62x | 0.33x | 0.65x | 0.36x | 3.76x | 2.27x | 0.99x | 0.99x |
| Debt / EBITDA | - | - | - | - | - | - | - | 9.05x | 3.46x | 7.09x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 3.17x | -0.14x | -0.14x |
| Interest Coverage | -18.39x | -8.68x | -6.70x | -6.21x | -10.40x | -8.71x | -1.47x | 3.48x | 8.80x | 28.93x |
| Total Equity | -168.72M▲ 0% | -4.83M▲ 97.1% | 54.65M▲ 1232.6% | 103.89M▲ 90.1% | 67.85M▼ 34.7% | 187.38M▲ 176.1% | 137.2M▼ 26.8% | 228.6M▲ 66.6% | 473.1M▲ 107.0% | 494.01M▲ 0% |
| Equity Growth % | -534.98% | 97.14% | 1232.62% | 90.11% | -34.69% | 176.14% | -26.78% | 66.62% | 106.95% | 329.18% |
| Book Value per Share | -11.65 | -0.25 | 3.85 | 4.21 | 2.46 | 6.34 | 4.22 | 6.49 | 11.67 | 13.65 |
| Total Shareholders' Equity | -168.72M | -4.83M | 54.65M | 103.89M | 67.85M | 187.38M | 137.2M | 228.6M | 473.1M | 494.01M |
| Common Stock | 1K | 331.21M | 424.13M | 502.22M | 510.49M | 666.28M | 641.11M | 697.21M | 750.93M | 764.64M |
| Retained Earnings | -312.18M | -335.94M | -369.48M | -398.23M | -442.45M | -478.68M | -503.7M | -468.24M | -277.95M | -270.63M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -149K | -101K | -2K | -95K | -188K | -225K | -199K | -364K | 124K | 2K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TMDX Cash Flow Statement
TransMedics Group, Inc. (TMDX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -23.1M | -25.98M | -32.29M | -30.27M | -28.86M | -45.82M | -13.03M | 48.8M | 192.84M | 192.84M |
| Operating CF Margin % | -300.56% | -199.62% | -136.78% | -118.04% | -95.38% | -49.02% | -5.39% | 11.05% | 31.85% | - |
| Operating CF Growth % | 4.19% | -12.49% | -24.25% | 6.26% | 4.63% | -58.73% | 71.57% | 474.6% | 295.14% | 2205.66% |
| Net Income | -20.82M | -23.76M | -33.55M | -28.75M | -44.22M | -36.23M | -25.03M | 35.46M | 190.29M | 171.92M |
| Depreciation & Amortization | 630K | 769K | 1.22M | 1.58M | 1.82M | 3.48M | 8.18M | 19.76M | 27.18M | 32.91M |
| Stock-Based Compensation | 70K | 144K | 854K | 2.41M | 6.88M | 10.32M | 19.79M | 33.22M | 36.86M | 37.85M |
| Deferred Taxes | -316K | 1.01M | 336K | -431K | 0 | 0 | -1.66M | 0 | -83.54M | -82.48M |
| Other Non-Cash Items | 93K | 177K | 475K | 511K | 3.65M | 3.37M | 30.04M | 5.36M | 4.79M | -3.16M |
| Working Capital Changes | -2.75M | -4.33M | -1.63M | -5.59M | 3M | -26.76M | -44.35M | -45M | 17.25M | 63.17M |
| Change in Receivables | 454K | -2.51M | -3.17M | -218K | 840K | -21.68M | -33.82M | -34.31M | 13.95M | 51.56M |
| Change in Inventory | -2.5M | -2.7M | -4.12M | -1.74M | -4.89M | -8.02M | -28.09M | -8.35M | -7.72M | -13.62M |
| Change in Payables | -735K | 164K | 3.44M | -5.8M | 5.09M | -3.27M | 6.96M | -1.4M | -19K | 326K |
| Cash from Investing | 24.86M | 12.31M | -60.5M | -41.6M | 29.27M | 54.51M | -193.95M | -129.3M | -59.25M | -68.87M |
| Capital Expenditures | -263K | -418K | -165K | -455K | -3.52M | -11.91M | -151.85M | 0 | -59.25M | -68.87M |
| CapEx % of Revenue | 3.42% | 3.21% | 0.7% | 1.77% | 11.63% | 12.74% | 62.84% | 29.38% | 9.79% | - |
| Acquisitions | 0 | 0 | 60.34M | 41.14M | 0 | 107K | -14.89M | 441K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 25.12M | 12.72M | -60.34M | -41.14M | 0 | -107K | -27.21M | -129.74M | 0 | 0 |
| Cash from Financing | 3K | 22.06M | 92.72M | 75.55M | 1.39M | 167.93M | 400.42M | 22.87M | 16.86M | 17.59M |
| Debt Issued (Net) | 0 | 24.36M | 0 | 0 | 0 | 22.46M | 445.38M | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 97.37M | 74.97M | 0 | 139.85M | 0 | 22.87M | -138K | 10.87M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -138K | 1.69M |
| Other Financing | 3K | -2.3M | -4.64M | 584K | 1.39M | 5.61M | -44.96M | 0 | 17M | 6.72M |
| Net Change in Cash | 2.1M▲ 0% | 8.3M▲ 295.7% | -149K▼ 101.8% | 4.49M▲ 3112.8% | 999K▼ 77.7% | 175.6M▲ 17477.8% | 193.63M▲ 10.3% | -58.16M▼ 130.0% | 151.72M▲ 360.9% | 169.53M▲ 0% |
| Free Cash Flow | -23.36M▲ 0% | -26.4M▼ 13.0% | -32.45M▼ 22.9% | -30.72M▲ 5.3% | -32.38M▼ 5.4% | -57.72M▼ 78.3% | -192.09M▼ 232.8% | -80.94M▲ 57.9% | 133.59M▲ 265.0% | 151.36M▲ 0% |
| FCF Margin % | -303.98% | -202.83% | -137.48% | -119.82% | -107.01% | -61.76% | -79.5% | -18.33% | 22.06% | 23.8% |
| FCF Growth % | 8.7% | -13.02% | -22.91% | 5.33% | -5.41% | -78.25% | -232.77% | 57.86% | 265.04% | 339.39% |
| FCF per Share | -1.61 | -1.37 | -2.28 | -1.24 | -1.17 | -1.95 | -5.91 | -2.30 | 3.30 | 3.30 |
| FCF Conversion (FCF/Net Income) | 1.11x | 1.09x | 0.96x | 1.05x | 0.65x | 1.26x | 0.52x | 1.38x | 1.01x | 0.88x |
| Interest Paid | 0 | 0 | 0 | 0 | 3.33M | 0 | 8.09M | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TMDX Key Ratios
TransMedics Group, Inc. (TMDX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -134.66% | -36.27% | -51.49% | -28.39% | -15.42% | 19.39% | 54.24% | 41.92% |
| Return on Invested Capital (ROIC) | - | -176.4% | -57.44% | -21.67% | -29.56% | -33.73% | -13.81% | 8.41% | 18.84% | 18.84% |
| Gross Margin | 27.81% | 44.05% | 58.73% | 64.88% | 69.92% | 69.84% | 63.77% | 59.36% | 59.92% | 59.09% |
| Net Margin | -270.96% | -182.5% | -142.12% | -112.13% | -146.11% | -38.77% | -10.36% | 8.03% | 31.43% | 27.04% |
| Debt / Equity | - | - | 0.62x | 0.33x | 0.65x | 0.36x | 3.76x | 2.27x | 0.99x | 0.99x |
| Interest Coverage | -18.39x | -8.68x | -6.70x | -6.21x | -10.40x | -8.71x | -1.47x | 3.48x | 8.80x | 28.93x |
| FCF Conversion | 1.11x | 1.09x | 0.96x | 1.05x | 0.65x | 1.26x | 0.52x | 1.38x | 1.01x | 0.88x |
| Revenue Growth | 23.77% | 69.38% | 81.33% | 8.62% | 18.03% | 208.83% | 158.53% | 82.74% | 37.13% | 30.24% |
TMDX SEC Filings & Documents
TransMedics Group, Inc. (TMDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
TMDX Frequently Asked Questions
TransMedics Group, Inc. (TMDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
TransMedics Group, Inc. (TMDX) reported $635.9M in revenue for fiscal year 2025. This represents a 10141% increase from $6.2M in 2016.
TransMedics Group, Inc. (TMDX) grew revenue by 37.1% over the past year. This is strong growth.
Yes, TransMedics Group, Inc. (TMDX) is profitable, generating $171.9M in net income for fiscal year 2025 (31.4% net margin).
Dividend & Returns
TransMedics Group, Inc. (TMDX) has a return on equity (ROE) of 54.2%. This is excellent, indicating efficient use of shareholder capital.
TransMedics Group, Inc. (TMDX) generated $151.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More TMDX
TransMedics Group, Inc. (TMDX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates